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MECHANISMS FOR THE RECOVERY OF TYPE 2 DIABETES           
MELLITUS FOLLOWING BARIATRIC SURGERY 
 
DANIELLE GAMBY 
ABSTRACT 
Studies have shown that following bariatric surgery, there is an almost 
immediate reversal of type 2 diabetes. However, there still remain questions as 
to why this occurs and what possible explanations there may be.  
This paper aims to focus on several studies that have found a reversal of 
diabetes in obese patients who have undergone bariatric surgery. Furthermore, it 
explores several possibilities for the reasons behind this reversal including the 
role of AMP-activated protein kinase, the incretins gastric inhibitory peptide and 
glucagon-like peptide-1, and also looks at genetics. 
Bariatric surgery and a description of certain mechanisms are first 
described for an understanding. Following is a literature review of published 
studies on bariatric surgery, the reversal of diabetes following the procedure, and 
roles of AMPK and incretins.  
Because of the possibility that reduced caloric intake may not be the major 
factor in the diabetic reversal, it is suggested that further research be done on 
obese and normal weight patients and observe the levels of the mentioned 
mechanisms and also various genes to see if they offer a more thorough 
explanation. 
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INTRODUCTION 
Obesity is a growing trend within developed countries, including the United 
States. From 2011-2012, it was found that 34.9% of adults 20 years of age and 
older were obese (Ogden, Carroll, Kit, & Flegal, 2014). With obesity comes a 
plethora of other health issues including cardiovascular disease, cancer, 
hypertension, and diabetes. Furthermore, obesity contributes to the insulin 
resistance syndrome, which includes type 2 diabetes (Steinberger & Daniels, 
2003).  
The costs associated with obesity and metabolic disorders is a concern. 
The federal government spent $147 billion on obesity-related health care for 
people in 2008 (“Adult Obesity Facts, 2014). While the costs associated with 
bariatric surgery may seem daunting, the overall long-term benefits outweigh this 
initial cost. By combating and treating those who are obese and suffer from 
health related disease, the long-term costs for each of these patients will go 
down and not only improve a person’s life financially, but also physically and 
emotionally.  
Previous studies have shown that, in morbidly obese patients, bariatric 
surgery diminishes type 2 diabetes; reversing it prior to a major weight loss. It is 
here that we remain perplexed by the mechanism in which this happens, 
including the explanation of why patients additionally have a decreased 
susceptibility to other metabolic syndromes and decreased mortality. By 
exploring studies showing the effects of bariatric surgery and the decrease in 
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associated co-morbidities, perhaps the explanation lies in mechanisms of the 
body such as AMP-protein kinase (AMPK) and sirtuins, especially gastric 
inhibitory peptide (GIP) and glucagon-like peptide-1 (GLIP-1). Additionally, the 
role that genetics plays in the onset and acceleration of disease must be 
considered as it too may provide an explanation for the reversal. 
Specific Aims 
Over time, bariatric surgery has been used to help morbidly obese patients 
lose weight. Studies have also shown that, in addition to the loss of weight, 
subjects have also shown great improvement in existing co-morbidities. Of 
notability to this paper is the almost immediate reversal of type 2 diabetes (also 
known as noninsulin-dependent diabetes mellitus, or NIDDM). 
This paper aims to analyze the reversal of NIDDM following bariatric surgery, 
and to explore the possible explanations, besides weight loss, including certain 
mechanisms of the body and also a possible role of genetics. Furthermore, 
following analyses, there is the question of bariatric surgery being considered for 
patients who are of normal weight and have NIDDM. Specifically: 
1. Data from previous studies will be discussed to first identify that diabetes 
reversal does indeed occur following bariatric surgery, even more quickly 
than weight loss. 
2. Papers will be explored that offer explanations as to why the reversal of 
NIDDM occurs. 
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3. More recent explanation will be reviewed, such as the role of several 
mechanisms of the body. 
These studies offer a background of type 2 diabetes reversal happening 
almost immediately following surgery. Additionally, they offer insight as to why 
this occurs, suggesting that the loss of weight may not be the key factor, and 
suggest the role of other body processes. Therefore, this paper will explain how 
NIDDM is reversed following bariatric surgery and what factors may play a role in 
this reversal. 
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BACKGROUND 
According to the American Diabetes Association (ADA), as of 2012 9.3% 
of the American population had diabetes (“Statistics about Diabetes,” 2014). This 
translates into 29.1 million Americans with an incidence of 1.7 million new 
diagnoses per year; down from 1.9 million in 2010 (“Statistics about Diabetes,” 
2014). Nevertheless, diabetes remains the 7th leading cause of death in the 
United States with a total cost of $245 billion for diagnosed diabetes in 2012 
(“Statistics about Diabetes,” 2014).  
With diabetes comes a long list of complications and co-morbidities 
including, but no limited to cardiovascular disease, kidney disease, blindness and 
eye problems, and amputations (“Statistics about Diabetes,” 2014). To prevent 
complications such as these, it is important for those diagnosed with type 2 
diabetes to closely monitor their blood glucose levels and engage in a healthy 
lifestyle consisting of regular exercise and healthy eating.   
Type 2 diabetes is characterized by high blood glucose levels due to 
either insufficient production of insulin by the pancreatic beta cells or when the 
body’s tissues become resistant to normal or high levels of insulin (McCulloch, 
Nathan, & Mulder, 2014). About 95% of those diagnosed with diabetes are those 
with type 2 (“Statistics about Diabetes,” 2014). Unlike in type 1, where the body 
does not produce any insulin, with type 2 diabetes, previously known as non-
insulin dependent diabetes (NIDD), the body produces insulin, however, the 
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pancreas does not make enough or the body does not utilize it well enough 
(“Type 2 Diabetes Overview”).  
The current treatment for type 2 diabetes is insulin therapy with the 
underlying goal to achieve glycemic control (Moghissi, M.D.). There are several 
causes associated with diabetes which may explain why the exact mechanism 
for the reversal of the disease following bariatric surgery remains unclear. These 
factors include a person’s lifestyle habits, the environment, and genetic 
predisposition. 
Financial costs 
In 2008, the federal government spent $147 billion on obesity-related 
health care, and the cost for medical care for each of those who are obese is 
$1,429 more than what a person who is of normal weight spends (“Adult Obesity 
Facts, 2014). While the surgery itself is expensive and may accrue additional 
costs due to complications and long-term treatment, the benefits of the surgery 
seem to outweigh the costs. In addition to weight loss, bariatric surgery reverses 
many co-morbidities, including diabetes, thus improves a person’s overall quality 
of life. With the reversal of co-morbidities comes the decreased cost in 
medication to treat the obesity-related illnesses and less frequency in doctor’s 
visits.  
The average cost for bariatric surgery, without insurance, ranged from 
$18,000 - $35,000, and around a $5,000 deductible with insurance (Elliot, 2012). 
The prices depends on several factors such as the type of procedure, location, 
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experience of the surgeon and reputation of the hospital, type of insurance, and 
risk. In addition to costs for the surgery itself, there are also costs associated with 
pre- and post-operative care, complications that may occur, and long term 
treatment and changes such as cosmetic surgery for getting rid of excess fat, 
and buying a new wardrobe. Nevertheless, money is saved in the long run 
because of the increase in overall quality of life. With the reduction of co-
morbidities, especially diabetes, there are no longer costs for medication, check-
ups, and complications that may occur because of these co-morbidities.  
The following chart was created to show the costs for the procedure broken down 
into more specifics: 
Bariatric Surgery Associated Costs 
Bariatric surgery (no 
insurance) 
$15,000 - $35,000; average of $22,000 
Bariatric Surgery (with 
insurance) 
$5,000 deductible 
Nutritionist  $50 - $100/visit 
Follow-up with bariatric 
surgeon 
Free – usually covered by insurance 
Complications with the 
surgery 
Free if the surgery was covered by insurance 
(includes treatment for the complication) 
Nutritional supplements $50/month 
 
________________________________________________________________ 
According to a study done on the economic impact of bariatric surgery, it 
was found that initial investment for bariatric surgery was returned within 4 years 
for open surgery patients and 2 years for laparoscopic surgery (Cremieux, et al., 
2008). Furthermore, those who underwent the surgery spent annually $930 on 
Table 1. Associated Costs for Bariatric Surgery (Obesity Coverage, 2013) 
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drug costs versus $1,123 for those who did not have the surgery (Cortez & 
Prettypiece, 2010).  
Overall quality of life may be a reason obese people seek help through 
bariatric surgery. An article by Washington University – St. Louis, did a study on 
people’s perception on the quality of life by attempting to quantify people’s 
observations (Straight, 2011). In the United States, $50,000 is the upper limit in 
order for a medical treatment to be considered cost effective (Straight, 2011). 
This number measures the true value of treatment looking at a person’s quality 
and length of life and is called the per-quality-adjusted life year (QALY) (Straight, 
2011). The study found that, for the extremely obese with a BMI of 50 or more, 
the cost of bariatric surgery is less than the health care costs associated with 
being extremely obese (Straight, 2011). The following table shows the associated 
costs for subjects with varying BMI’s and with or without obesity-related health 
problems. 
BMI Cost per QALY (USD) 
40-50 without obesity-related 
disease(s) 
$3,800 
40-50 with obesity-related disease(s) $1,900 
35-40 without obesity-related 
disease(s) 
$3,900 
35-40 with obesity-related disease(s) $2,400 
 
 
Table 2. Costs for Obese Subjects With and Without Obesity-Related 
Diseases (Straight, 2011) 
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These results show that, even as one is healthier, the overall costs for 
bariatric surgery were less than the cost for not getting the surgery, and therefore 
the costs were well under the $50,000 cap on the quantified quality of life. 
Bariatric Surgery 
Bariatric surgery is a procedure used to help obese patients lose weight 
by restricting the amount of food intake and decreasing the stomach and 
intestine size so that less food and nutrients are absorbed. This type of 
procedures is usually only performed after a person has tried all other means of 
losing weight (“Bariatric Surgery for Severe Obesity”, 2011). There are several 
types of bariatric surgeries including adjustable gastric band (AGB), Roux-en-Y 
gastric bypass (RYGB or simply gastric bypass), biliopancreatic diversion with a 
duodenal switch (BPD-DS), and vertical sleeve gastrectomy (VSG) (Jossart, 
n.d.). Each of these types vary in benefits and risks and it is important for the 
patient and physician to go over each of these to decide on the best option.  
The types of bariatric surgery have three common methods in the way that 
they work, (1) restrictive in which the size of the stomach is shrunk to decrease 
the amount of food it can hold (Jossart, n.d.). This in turn, decreases the amount 
of food a person eats and makes a person feel full much sooner when eating. 
The surgeries especially focused on this are the adjustable gastric banding (lap 
band surgery) and the gastric sleeve (Jossart, n.d.). (2) Malabsorptive where part 
of the digestive system is removed limiting the amount of calories and nutrients 
the body absorbs (Jossart, n.d.). (3) Combination in which the components of 
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restriction and malabsorption are combined (Jossart, n.d.). Most notable are the 
gastric bypass and duodenal switch (Jossart, n.d.).  
When a person is considering bariatric surgery, there are several factors 
involved including body mass index (BMI), eating habits, health conditions 
related to obesity, and previous stomach surgeries  (“Bariatric Surgery for Severe 
Obesity, 2011). Figure 1 shows the 4 types of bariatric surgery. This paper will 
focus on Roux-en-Y gastric bypass and biliopancreatic diversion with a duodenal 
switch. 
 
 
 
 
 
 
 
 
 
________________________________________________________________ 
The normal digestive process consists of the intake of food in which it is 
then moved along the digestive tract while being absorbed by digestive juices 
and enzymes. The pathway for food is from the mouth down the esophagus to 
Figure 1. Types of Bariatric Surgery (Mandal, 2014) 
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the stomach. It is at the stomach where strong digestive juices further break 
down the food. Following the stomach, it moves into the intestine, where in the 
duodenum, the first part of the small intestine, bile and pancreatic juice speed up 
digestion (“Bariatric Surgery for Severe Obesity, 2011). The duodenum is where 
most of the iron and calcium we eat are absorbed (“Bariatric Surgery for Severe 
Obesity, 2011). The rest of the small intestine take up the leftover food and the 
food particles unable to be digested by the small intestine are then taken up by 
the large intestine. 
With bariatric surgery, this long process of food digestion is cut short by 
decreasing the allowance of food intake and the amount of food the stomach is 
able to hold. The amount of weight a person is able to lose varies greatly on the 
surgery and habits following such as dietary intake and lifestyle choices. In 
addition to weight loss, previous co-morbidities, such as type 2 diabetes, may 
undergo complete reversal and improve the overall quality of life. 
Having a youth undergo bariatric surgery is a choice that is carefully 
planned and thought out. While the long-term effects are unpredictable, it may be 
a suitable option for a youth who has tried all other means for losing weight. 
Typically, candidates should only consider surgery after trying unsuccessfully for 
at least 6 months to lose weight (“Bariatric Surgery for Severe Obesity, 2011). It 
can be an emotional process, so both the parents and child should carefully 
consider the lifestyle changes that will be associated with having the surgery. 
Additionally, the child should be extremely obese (a BMI greater than or equal to 
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40), be at their adult height, and have serious health conditions associated to the 
obesity (“Bariatric Surgery for Severe Obesity, 2011). Table 3 explains in more 
detail the costs and risks associated with each types of bariatric surgery. 
________________________________________________________________ 
Table 3. Types of Bariatric Surgery Explained. *Assuming insurance does not 
pay. Based on Bariatric Surgery Source’s annual weight loss surgeon cost 
survey (Jossart, n.d.) 
 
 
 
Adults have a similar criteria In order to qualify for bariatric surgery. In 
addition to previously being unsuccessful at weight loss using other means, one 
must have a body mass index (BMI) greater than 40 or a BMI between 35 and 40 
and have additional co-morbidities due to the excessive weight. 
 
 
Types of 
Bariatric 
Surgery 
Category Average Long-
Term Excess 
Weight Loss 
(approx. %) 
Complication 
Rate 
Average 
Cost* (USD) 
Gastric 
Bypass 
(Roux-en-Y) 
Combination 
(primarily 
restrictive) 
50% - 70% 
 
Up to 15% $24,000 
Gastric Sleeve 
(Vertical 
Sleeve 
Gastrectomy) 
Restrictive 65% - 75% Up to 10% $19,000 
Biliopancreatic 
Diversion with 
Duodenal 
Switch 
Malabsorptive 65% - 75% Up to 24% $27,000 
Gastric 
Banding (i.e. 
Lap Band) 
Restrictive Extremely 
variable ranging 
from 25% - 80% 
Up to 33% $15,000 
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Roux-en-Y Gastric Bypass (Gastric Bypass) 
Roux-en-Y gastric bypass surgery, also known as simply gastric bypass 
surgery, is the most commonly used type of bariatric surgery (Jossart, n.d.). This 
is a combination type surgery using both restrictive and malabsorptive 
techniques, however, it is mainly restrictive in nature (Jossart, n.d.). As described 
by Dr. Jossart in the article, the procedure is as follows: 
The surgeon: 
1. Cuts and staples the top portion of the stomach to create a small 
pouch at the end of the esophagus. 
2. Leaves the remainder of the stomach attached to the top of the small 
intestines. 
3. Goes further down the small intestine, cuts it, and attaches it to the 
pouch. 
4. Takes the end of the small intestine that is still connected with the non-
pouch portion of the stomach and attaches it to the bottom of the 
“Roux limb.” This allows digestive juices produced by the stomach to 
meet up with the food in the intestines. 
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Figure 2. Roux-en-Y Gastric Bypass: The stomach before and after the 
bariatric surgery (Roux-en-Y Gastric Bypass (RYGB), 2014). 
________________________________________________________________ 
Figure 2 compares a normal stomach to one that has undergone bariatric 
surgery. It shows the portions of the stomach that are bypassed and how the 
food and digestive juices meet up and head towards the intestines. 
Following gastric bypass surgery, the weight loss is not automatic and 
drastic lifestyle changes must occur and continue. As with any surgery, 
complications can occur, and gastric bypass surgery is one of the more risky 
bariatric procedures (Jossart, n.d.). Some of the complications include 
dehydration, swallowing, gallstones, and hair loss (Jossart, n.d.). 
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Biliopancreatic Diversion with Duodenal Switch (BPD-DS) 
Another form of bariatric surgery is the biliopancreatic diversion with the 
duodenal switch (BPD-DS). This form of surgery is prominently of the 
malabsorptive type and results in the most weight loss out of the bariatric 
procedures (Jossart, n.d.). As described by Guidone, et.al. (2006), the procedure 
for the BPD-DS is as follows: 
The residual volume of the stomach is about 400 ml. The small bowel is 
transected at 2.5 m from the ileo-caecal valve, and its distal end is 
anastomosed to the remaining stomach. The proximal end of the ileum, 
comprising the remaining small bowel carrying the bilio-pancreatic juice 
and excluded from food transit, is anastomosed in an end-to-side fashion 
to the bowel 50 cm proximal to the ileo-caecal valve. Consequently, the 
total length of absorbing bowel is brought to 250 cm, the final 50 cm of 
which (the so-called common channel) represents the site where ingested 
food and bilio-pancreatic juices mix. 
Figure 3 shows how BPD-DS works – how part of the stomach and small 
intestine are connected to bypass a large part of the stomach and decrease the 
length at which food and nutrients are absorbed. 
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Figure 3. Biliopancreatic Diversion with Duodenal Switch (“Bariatric Surgery 
Procedures, 2014). 
________________________________________________________________ 
 
AMP-activated Protein Kinase (AMPK) 
 Known for its role in cellular metabolism, AMP-activated protein kinase 
may help us better understand the diminishing factor of diabetes in obese 
patients following bariatric surgery (Hardie, 2011). Activation of AMPK is via 
increases in both AMP and ADP, and thus metabolic stresses including stimuli 
such as hypoxia, fuel deprivation and muscle contraction. 
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 AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme with 7 
genes consisting of 3 subunits – a catalytic subunit (α) and two regulatory 
domains (β and γ) (Ruderman, Carling, Prentki, & Cacicedo, 2013). Figure 4, 
taken from Ruderman, Carling, Prentki, & Cacicedo’s paper (2013), shows the 
structure of AMPK where each subunit has a number of isoforms, where α has 
two, denoted α1 and α2, β also has two, denoted β1 and β2, and γ has three 
isoforms, denoted γ1, γ2, and γ3. Thus, in total, these twelve heterotrimeric 
combinations can be formed through coexpression of the α, β, γ subunits 
(Hardie, 2011). Each subunit, by itself and non-bound, is unstable thus when one 
subunit is overexpressed, it may become a dominate and compete for binding of 
the other two (Hardie, 2011). 
 
  
 
 
 
 
 
 
 
Figure 4. AMPK Structure ((Ruderman, Carling, Prentki, & Cacicedo, 2013). 
________________________________________________________________ 
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AMPK regulates a vast array of physiological events, including factors 
related to insulin resistance (IR). Overall, AMPK increases cellular ATP 
generation and thus decreases ATP use for less critical processes. Figure 5 lists 
all of the possible effects of increased AMPK activation (Ruderman, Carling, 
Prentki, & Cacicedo, 2013). 
 
  
 
 
 
 
 
 
 
Figure 5. Actions of AMPK (Ruderman, Carling, Prentki, & Cacicedo, 
2013). 
________________________________________________________________ 
Also shown in Figure 4, from Ruderman, Carling, Prentki, & Cacicedo’s 
(2013) paper, are the subunits of the γ subunit, called cystathionine-β-synthase 
(CBS) domains. There are four of these on the γ subunit which form four 
potential adenine nucleotide-binding sites. Studies on structural and in vivo 
binding have shown, however, that the γ subunit binds only three nucleotides. 
Sites 1 and 3 serve as the exchangeable binding sites, site 2 is unoccupied, and 
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site 4 serves as the nonexchangeable, AMP-bound binding site (Ruderman, 
Carling, Prentki, & Cacicedo, 2013).. 
 Figure 4 also shows the threonine 172 residue which binds to the catalytic 
α subunit. There is a carbohydrate-binding molecule (CBM), or glycogen-binding 
domain, on the β subunit, which is found in various enzymes involved in 
carbohydrate metabolism (Ruderman, Carling, Prentki, & Cacicedo, 2013). The 
CBM domain on the β subunit has numerous implications. AMPK is inhibited 
when glycogen or other branched-chain sugars bind to this region (Ruderman, 
Carling, Prentki, & Cacicedo, 2013). In return, the mechanism of activation of 
AMPK also takes place in this domain by small-molecule activators. 
 Activation of AMPK, involving the threonine 172, is catalyzed by two 
protein kinases. The first is liver kinase β1 (LKB1), a tumor suppressor, and is 
activated via changes in energy (Hardie, 2011). The second is active by 
increases in intracellular calcium and is thus called calcium calmodulin-
dependent protein kinase β (CAMKKβ) (Hardie, 2011). Figure 6, adapted from 
“AMPK, Insulin Resistance, and the Metabolic Syndrome,” shows how AMPK is 
regulated. Phosphorylation of threonine 172 (thus becoming phosphothreonine) 
on the α subunit by either LKB1 or CAMKKβ, activates AMPK (Ruderman, 
Carling, Prentki, & Cacicedo, 2013). Protein phosphatases then deactivate 
AMPK through dephosphorylation, however, the kinase is maintained in an active 
conformation because of the binding of ADP and AMP to the γ subunit of AMPK 
(Ruderman, Carling, Prentki, & Cacicedo, 2013). 
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Figure 6. AMPK Regulation (Ruderman, Carling, Prentki, & Cacicedo, 2013). 
________________________________________________________________ 
Hallmarks of metabolic syndrome and other associated conditions include 
insulin resistance and hyperinsulinemia. With the addition of exercise and a 
regulated amount of caloric intake, insulin sensitivity is increased, and thus the 
prevalence of disorders such as type 2 diabetes mellitus, hypertension, and 
certain cancers is decreased. While a person is exercising, AMPK is activated in 
specific and underappreciated tissues, therefore, it may be that the underlying 
benefits of exercise may be due to the underlying effects of AMPK (Ruderman, 
Carling, Prentki, & Cacicedo, 2013).  
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Sirtuins 
 Sirtuins are a class of NAD-dependent histone/protein deacetylases of 
which seven have been identified in mammalian cells (Ruderman, et al., 2010). 
Of the seven sirtuins, the one concentrated on in this study is the silent 
information regulator T1 (SIRT1). As with AMPK, SIRT1 regulates a number of 
metabolic processes, and has many similarities with AMPK in terms of regulation 
and actions on various processes including cellular metabolism and inflammation 
(Ruderman, et al., 2010). This is shown on fig 7. 
 
  
 
 
 
 
 
Figure 7. Factors Affecting AMPK and SIRT’s Leading to Disease (Ruderman, et 
al., 2010). 
________________________________________________________________ 
From the discovery that sirtuins are a class of NAD-dependent protein 
deacetylases comes the notion of sirtuins and their effects on aging. It suggested 
that sirtuins may play a role in caloric restriction (CR) because, through a 
person’s diet, they may regulate life span in concurrence with metabolism 
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(Guarente, 2007). Figure 8, adapted from Guarente’s 2007 paper, shows the 
various mechanisms SIRT1 targets. These processes are grouped into two 
classes, stress management and metabolism. Especially important for our study 
is the effect of SIRT1 on metabolism by way of insulin production and glucose 
homeostasis. Figure 8 shows that suppression of the uncoupling protein UCP2 
positively regulates insulin secretion in β cells, thus SIRT1 would be an efficient 
protein for the clearance of glucose from the blood (Guarente, 2007). 
 
  
 
 
 
 
 
 
 
Figure 8. SIRT1 Mechanisms (Guarente, 2007). 
________________________________________________________________ 
The regulation of SIRT1 is similar to AMPK in that it is dependent on the 
amount of caloric intake. While its regulation is not as well understood as that of 
AMPK, there are some factors that are known. In Figure 9 it is shown how lack of 
caloric intake will lead to an eventual increase in SIRT1 (Ruderman, et al., 2010). 
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NAM phosphoribosyltransferase (Nampt) catalyzes the conversion of 
nicotinamide (NAM) to NAD+, which, in turn, decreases both NAM and NADH 
(Ruderman, et al., 2010). Both NAM and NADH inhibit SIRT1. On the other hand 
Nampt activates SIRT1 through its role of catalyzing the conversion of NAM to 
NAD+ and thus increasing cellular NAD+ and decreasing NAM (Ruderman, et al., 
2010). The opposite effect of abundant nutrient intake shows reversal effects. 
 Figure 9 shows some of the commonalities between SIRT1 and AMPK. 
For instance, caloric restriction and exercise both activate SIRT1 and AMPK 
which eventually leads to a range of actions, either inhibitory or activating. 
 
 
 
 
 
 
 
 
 
Figure 9. Similarities between AMPK and SIRT1 (Ruderman, et al., 2010). 
________________________________________________________________ 
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Gastric Inhibitory Peptide (GIP) and Glucagon-like peptide-1 (GLP-1)  
Gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) are 
incretin hormones secreted from the intestinal tract following a meal, GIP is 
released from intestinal K cells and GLP-1 is released from I cells following food 
intake (Seino, Fukushima, Yabe, 2010). They become effective after binding to 
their G-protein receptor which leads to a secretion of insulin.  
Figure 10. Functions of GIP and GLP-1 (Seino, Fukushima, Yabe, 2010). 
_______________________________________________________________ 
Figure 10 gives a summary of the various influences GIP and GLP-1 have 
on various organs of the body. As shown, both GLP-1 and GIP increase insulin 
release in the pancreas, but decrease that of glucagon. They have opposing 
effects on the GI tract where GLP-1 delays gastric emptying while GIP decreases 
gastric acid secretion. 
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Gastric inhibitory peptide is glucose-dependent and activates insulin 
secretion following a meal (“Gastric Inhibitory Peptide,” 2014). On Diabetes Daily 
(2014), it explains that, regarding the pathology of GIP, people who have type 2 
diabetes do not respond to GIP and therefore, as studied in knockout mice, if 
there is no GIP, then there is resistance to obesity.  
GLP-1 is another incretin hormone and has a profound effect on 
stimulating the release of insulin from pancreatic β cells. The big downfall of 
GLP-1, is that researchers discovered that is was broken down by dipeptidyl 
peptidase-4 (DPP-4), an enzyme, and therefor had a very short active life 
(Marino, 2009). To solve this issue, there is a protein named exendin-4 that 
mimics the actions of GLP-1, such as stimulation of insulin secretion, 
suppression of glucagon, and the slowing of stomach emptying, but has a 
prolonged half-life in the blood (Marino, 2009). Thus, exendin-4 is used as part of 
therapy for those with type 2 diabetes. Because of what is known as the “incretin 
effect,” GLP-1 has been implicated in playing a major role in Type 2 diabetes 
(Abrahams, 2014). As Abrahams explains in “GLP-1 and Type 2 Diabetes,” 
(2014) the way the “incretin effect” works is that patients are administered an oral 
dose of glucose, and for patients who have diabetes, the increase in insulin is 
higher than that seen with an intravenous injection of glucose. This high rise of 
insulin with the oral intake of glucose versus intravenously is seems to be linked 
to a decrease in the levels of GLP-1 (Abrahams, 2014). 
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PRESENTATION OF PUBLISHED RESULTS 
 There are many studies that have shown the beneficial effects of bariatric 
surgery as not only promoting weight loss, but also as a way to reduce obesity-
related diseases, especially diabetic reversal. Beginning the review will be 
literature that has found rapid reversal of diabetes following bariatric surgery 
followed by studies that have explored the reasons for this. 
In addition to weight loss, bariatric surgery may also play a major role in 
reversing many co-morbidities, including diabetes. It is unclear the exact 
mechanism that causes this, but there are many studies showing up that several 
factors may play a role.  
Greenville Gastric Bypass 
In 1980, the “Greenville bypass” study began recruiting patients to better 
understand bariatric surgery as a treatment for type 2 diabetes (also known as 
NIDD) (Pories, et al., 1995). They not only wanted to understand the mechanism 
behind the reversal, but also wanted to see if the results were long term, 
effective, and safe (Pories, et al., 1995). 
Over the span of 14 years, the “Greenville bypass” study treated 608 
morbidly obese patients with gastric bypass surgery and monitored their 
immediate and long-term results. The patient population was a mixed group of 
racial backgrounds including white and African American with various 
occupations and ranged in age from 14 to 64 years old (Pories, et al., 1995). Out 
of the 608 morbidly obese patients, 165 (27%) had NIDDM and another 165 
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(27%) had impaired glucose tolerance (IGT), while 353 (58.1%) had hypertension 
(Pories, et al., 1995). 
The qualifications for the “Greenville bypass” study followed the guidelines 
for gastric bypass of having a body mass index (BMI) greater than or equal to 40 
or a BMI greater than or equal to 35 in addition to other obesity-related co-
morbidities. If a patient did qualify, over a span of several months, he or she and 
their family members would be evaluated to go over the process in detail and 
make sure they all understood how the operation would work and the effects 
associated with the surgery. Additionally, if a patient did have serious health 
problems, they would need to be stabilized before the operation. 
Prior to undergoing the surgery, it is also important to understand how 
likely or able the patient is able to keep up with these lifestyle changes, if the 
surgery maintains the reversal of NIDDM, and if there are any harmful 
consequences that may occur due to the surgery. Gastric bypass surgery may 
provide an option for those who are obese and have type 2 diabetes and/or other 
co-morbidities, and while a reversal of diabetes is seen quite quickly, it is also 
important to understand the long-term consequences associated with having the 
surgery.  
A three year report on the “Greenville Gastric Bypass” was published by 
Flickinger, et al. (1984) to discuss their findings after following a sample of 
patients for 3 years after the procedure. The patient population studied at this 
time consisted of 210 subjects with 100% follow-up (Flickinger, et al., 1984). 
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They found that the subjects tended to reach their maximal weight loss 18 
months after the surgery with 209 out of the 210 patients losing over 29% of their 
original weight (Flickinger, et al., 1984). The overall goal for this report was to 
verify the safety and efficacy of the operation for treatment of obesity (Flickinger, 
et al., 1984). 
The final report was published in 1995 by Pories, et al (1995), and 
observed the patients over a span of 14 years, which is representative of 
understanding the long-term effects of the operation. The range in ages was a 
valid representation of the population, however, the lack of diversity in patient 
population was not well represented and may have been more representative 
had it included other backgrounds.  
The “Greenville bypass” study is significant to a better understanding of 
bariatric surgery and its role in diabetes reversal because it provides information 
showing that the long-term effects of the surgery are consistent with diabetes 
reversal granted that complications do not arise from surgery and that the patient 
maintains a healthy lifestyle. It also offers some clues as to why the reversal 
occurs. They suggest several conclusions and rules out others. One’s that I feel 
are especially mentionable are that Flickinger, et al (1984) reported that 3 
morbidly obese patients with NIDDM underwent the vertical banded gastroplasty, 
in which food intake is limited but does not bypass any section of the foregut, and 
they too saw a correction in the diabetes. Furthermore, the role of incretins may 
have something to do with it. As suggested in the text, when food is ingested, 
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incretins are released and signal insulin secretion which signals glucose uptake 
from the blood. The two incretins of particular importance are glucagon-like 
peptide 1 (GLP-1) and gastric inhibitory peptide (GIP). Thus perhaps there is a 
defective mechanism in the signaling for patients with NIDDM and following 
surgery, it is corrected.  
Swedish Obese Subjects Study 
While bariatric surgery may seem an ideal way to lose weight and possibly 
reverse co-morbidities, it does not come without risk. There had not been studies 
to specifically address whether weight loss actually decreases mortality rates, 
thus the Swedish Obese Subjects (SOS) study was formed in 1980 to assess the 
decline of mortality with bariatric surgery (Sjöström, 2007). 
The SOS study enrolled 4047 subjects, 2010 of whom underwent bariatric 
surgery while the other 2037 received conventional weight lost treatment and 
therefore served as the control group. The average time for follow up with the 
patients was 10.9 years and recruitment ran from September 1, 1987 to January 
31, 2001 (Sjöström, 2007). To be eligible, subjects must have been between the 
ages of 37 and 60 years old and have a BMI of 34 or more for men and 38 or 
more for women (Sjöström, 2007). The types of bariatric surgery performed 
varied and included nonadjustable or adjustable banding, vertical banded 
gastroplasty, and gastric bypass. 
The SOS study had a large cohort of patients representing society, 
however, race and ethnicity was not mentioned so there may have been a 
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limitation as to which ethnicities the study group represented. The follow-up rates 
for both groups were very high with 94%, 84%, and 66% at 2, 10, and 15 years 
for the study group and 83%, 75%, and 87% for the control group. 
A 2 year follow-up report on the SOS study looked at 1690 out of the 4047 
subjects to investigate the outcome of the bariatric surgery versus the control 
group. It is in this report that they saw a noticeable reduction in diabetes in the 
patients who underwent the surgery versus the controls (Sjöström, 1999). At this 
point in time, since it was only a 2 year follow-up for the subjects, the testers 
could not make a decision yet on long term goals such as a decrease in 
mortality, however, it is important to note that they had found this great reduction 
in diabetes in patients who underwent the procedure.  
Additionally, those conducting this report on the 2 year follow-up looked at 
845 controls and 845 bariatric surgery subjects and they found marked results 
between the two groups. For the control group, they found that after 2 years, 
body weight and BMI was unchanged (Sjöström, 1999). However, they found that 
the group that underwent bariatric surgery had, after 2 years, a drop in their body 
weight to 92.7 kg and the BMI was reduced, on average, to 32.4 kg/m2 and 
additionally saw that the waist/hip ratio also was reduced (Sjöström, 1999).  
In those that were treated with surgery, the incidence of diabetes was 
reduced 30-fold. Therefore, after several years, the reversal of diabetes was 
maintained bringing up the point the possibility of certain factors causing this 
reversal. Besides reduced food intake and reduced caloric intake, there must be 
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some other mechanisms causing this reversal because they did not see this 
difference in the control group where conventional weight loss methods were 
used. 
Mechanisms of Recovery from Type 2 Diabetes after Malabsorptive 
Bariatric Surgery 
While the SOS study showed that long-term mortality was decreased 
following bariatric surgery, and after 2 years of the surgery, patients saw a 
reversal of diabetes, the mechanism as to why this occurred was still not 
completely clear. Thus, a study was done to try and better understand the 
pathophysiology of the reversal of diabetes following bariatric surgery. 
In Mechanisms of Recovery from Type 2 Diabetes after Malabsorptive 
Bariatric Surgery, Guidone, et.al (2006) studied 10 diabetic and morbidly obese 
patients who underwent a biliopancreatic division (BPD) and closely monitored 
insulin sensitivity and circulating levels of incretins and adipokines. Their aim was 
to show that the weight loss itself was not the cause, but rather 
pathophysiological mechanisms involved in the rapid resolution of type 2 
diabetes. Before their study, weight loss was the main focus for the bariatric 
surgery and the mechanisms involved in the resolution of type 2 diabetes was an 
added benefit (Guidone, et al., 2006). The aim of Guidone, et.al (2006) was to 
show that bariatric surgery was effective in curing diabetes in both obese and 
normal weight individuals due to other internal mechanisms and not primarily due 
to weight loss. 
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Overall, the noteworthy findings from this study are that at 1 and 4 weeks 
following BPD, patients experience full reversal of type 2 diabetes without a 
drastic change in weight (Guidone, et al., 2006).  
The study here is not without limitations. Having an extremely small study 
sample may not be an appropriate representation of those who are obese and 
have NIDDM. While it seems that 10 subjects may not offer an acceptable 
representation, it did have benefits. Have the small sample size allowed the 
researchers to closely monitor the subjects and gather more information pertinent 
to the study. They were able to perform additional testing and not have to worry 
about losing patients or having them drop out because they were able to perform 
a more in-depth analysis while closely monitoring them. 
AMPK, Insulin Resistance, and the Metabolic Syndrome 
Some of the mechanisms within the body that may have something to do 
with the diabetes reversal following bariatric surgery are the actions of AMPK and 
SIRT1. With exercise, the levels of AMPK increase along with insulin sensitivity, 
while the levels of plasma insulin decrease (Ruderman, Carling, Prentki, & 
Cacicedo, 2013). Furthermore, AMPK has a wide spectrum of benefits on 
metabolic-associated diseases (Ruderman, Carling, Prentki, & Cacicedo, 2013). 
AMPK has been proposed to have a role in the inflammation and 
infiltration of immune cells in white adipose tissue which is involved with the 
development of insulin resistance in those that are obese (Gauthier, et al, 2011). 
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In a study published by Gauthier, et al (2011), noticeable differences were 
seen in the levels of AMPK for patients undergoing bariatric surgery. The 
researchers looked at obese patients undergoing bariatric surgery and obtained 
samples from abdominal subcutaneous, omental, and mesenteric adipose 
tissues and looked at inflammatory markers in each of these depots (Gauthier, et 
al, 2011). The results from the study correlate insulin resistance and insulin 
sensitivity with the levels of AMPK in patients who are obese and undergo 
bariatric surgery. 
Another study looked at AMPK and its role on insulin resistance and the 
metabolic syndrome. Ruderman, Carling, Prentki, and Cacicedo (2013) published 
a paper looking at the role of AMPK in the pathogenesis of insulin resistance (IR) 
and metabolic-syndrome associated diseases, including type 2 diabetes, and 
also how its role may be used in the treatment for these diseases. 
It appears that insulin resistance responds to changes in nutritional and 
physical activity and is not disease associated, but rather physiological 
(Ruderman, Carling, Prentki, and Cacicedo, 2013). Furthermore, it has been 
shown that exercise plays a role in the activation of AMPK, which, if utilized, can 
have a major impact on those with type 2 diabetes (“AMPK: Master Metabolic 
Regulator, 2014). Through exercise, plasma levels of insulin are diminished and 
it increases insulin sensitivity and decrease in hyperinsulinemia (Ruderman, 
Carling, Prentki, and Cacicedo, 2013). It just so happens that following exercise, 
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levels of AMPK are increased with exercise, therefore, perhaps it is attributable 
to a role in insulin sensitivity. 
Ruderman, Carling, Prentki, and Cacicedo (2013) focused on the 
implications of AMPK on its effects on adipose tissue. Some associations with 
the metabolic syndrome are the recruitment and activation of macrophages in 
adipose tissue with an increased number of these (Ruderman, Carling, Prentki, 
and Cacicedo, 2013). The researchers suggest that AMPK may play a role in 
preventing inflammatory activation of the adipose tissue macrophages possibly 
due to its positive effects on autophagy and mitochondrial function (Ruderman, 
Carling, Prentki, and Cacicedo, 2013). 
All of these studies have implicated the positive effects of bariatric surgery 
for obese, NIDDM patients. Either through research showing a decrease in 
mortality, an almost immediate reversal of diabetes following the procedure, or 
beneficial long-term effects, the literature offers insight into a possible reversal of 
diabetes for patients using bariatric surgery. 
Genetics 
A factor worth mentioning is that of the role that genetics plays in diabetes 
and the onset of the disease. In “Genetics and Diabetes: What’s Your Risk?” 
(2014), it states that “if a [person] has a parent with type 2 diabetes, the sibling’s 
risk is almost three times the general population risk. If both parents have type 2 
diabetes, the sibling has a fourfold risk, or nearly a 50% chance of developing 
diabetes.” 
 34 
 Genetics, however, is just a part of the cause of diabetes. Lifestyle and the 
environment are also factors that play a role in a person’s disposition for 
diabetes. Nevertheless, a gene that has been closely studied and may have to 
do with genetics and diabetes is the β3-adrenergic receptor gene. Walston, et al 
(1995) published a paper comparing the relationship between this gene and the 
time of onset of NIDDM. Expressed in visceral adipose tissue, the β3-adrenergic 
receptor gene has a role in regulation of the resting metabolic rate (Walston, et 
al, 1995). 
 The link between the β3-adrenergic receptor gene and the role it may play 
in the onset of NIDDM is that there may be abnormalities in the receptor. The β3-
adrenergic receptor, localized in adipose tissue, is coupled to guanine-
nucleotide-binding (G) proteins and spans the membrane seven times (Walston, 
et al, 1995). Walston, et al specifically looked at the Pima Indians, who have a 
high prevalence of disorders, for their study and evaluated the presence of 
mutations in the gene. 
 Their study group consisted of 642 Pima Indians where 390 had NIDDM 
and the other 252 served as controls, without NIDDM. The study offered insight 
into a possibility of genetics playing a role for the pre-disposition of diabetes. It 
did limit its study subjects to the Pima Indian ethnicity, which is not representative 
of a variety of population, however, they were able to study a greater number of 
those with NIDDM and who were genetically linked to further strengthen their 
findings.  
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DISCUSSION 
 Looking at several studies on bariatric surgery and the reversal of 
diabetes, it is clear that there is more to it than simply a decrease in food intake. 
Bariatric surgery is currently used for weight loss for obese patients who have 
tried all other forms of weight loss programs and have been unsuccessful. While 
the procedure is not without risks, there are also many benefits to having the 
surgery, including long-term quality of life. 
 The “Greenville bypass” study showed the long-term effects of 
gastric bypass surgery on the reversal of diabetes, with a 3 year report on the 
safety and efficacy of the surgery. The aim was not to show that the surgery 
reverses diabetes, but rather that it reverses the disease and keeps it under 
control for a long period of time. Additionally, they considered several reasons as 
to why this occurs. 
The figures below are representative of some of their data. Figure 11 
shows how rapidly the reversal of diabetes occurs following gastric bypass 
surgery. Pories, et al found that, following the surgery, of the 298 patients who 
presented with either NIDDM or IGT, 271 (91%) had maintained normal values of 
fasting blood glucose and glycosylated hemoglobin, while the other 27 (9%) 
continued to be diabetic. As of September 12, 1994, 121 of the 146 patients 
(82.9%) who had NIDDM prior to the surgery maintained normal blood glucose 
values and glycosylated hemoglobin (Pories, et al, 1995). Figure 11 shows the 
result from one of the patients’ who had presented with uncontrollable blood 
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glucose levels. It represents how quickly the reversal occurred following surgery. 
The patient initially had a fasting blood glucose level of 495 mg/dL, 
 
 
 
Figure 11. “Greenville Gastric Bypass” Results Showing How Quickly the 
Hyperglycemia Occurs Following Gastric Bypass (Pories, et al, 1995). 
______________________________________________________________ 
but by the 6th day post-operatively, she no longer required insulin and after the 
first month her fasting blood glucose fell to 155 mg/dL. 
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Figure 12. Comparison of Blood Glucose and Blood Insulin in Patients Following 
Surgery in 3 Groups Who Were Lean Controls, Morbidly Obese with NIDDM, and 
Morbidly Obese non-NIDDM (Pories, et al, 1995). 
 
Figure 12 compares three patient types, one with NIDDM, one who is 
morbidly obese without NIDDM, and one who is a lean control. The figure 
compares the levels of glucose and insulin prior to and following the surgery. For 
the patient with NIDDM, the glucose levels fall rapidly within just 2 days following 
the surgery as compared to the other two patients, suggesting that several 
factors may contribute to the diabetes reversal. 
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To better understand bariatric surgery and the reason for the reversal of 
NIDDM, it may be helpful to know of any complications may occur due to the 
procedure and how a person’s risk of mortality is affected. With controlled weight 
loss, such as bariatric surgery, the SOS study aimed to verify that the person’s 
overall mortality rate decreased.  
 
 
Figure 13. SOS Study: Cumulative Mortality Rates Between the Control Group 
and Surgery Group (Sjöström, et al 2007). 
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Figure 13 shows the cumulative mortality rate of patients in the control 
group versus those in the study group. Over the course of 16 years of follow-up, 
129 (6.3%) of patients died in the control group while 101 (5.0%) died in the 
study group (Sjöström, et al 2007). Overall, it is shown that bariatric surgery does 
indeed reduce the mortality of patients who undergo the procedure for controlled 
weight loss with the added benefits of reducing or reversing other co-morbidities.   
It is shown that mortality decreases with those who undergo bariatric 
surgery. But now it is important to understand how and why. In the study done by 
Giodone, et.al., the researchers believed that full reversal of diabetes would 
occur in these subjects following BPD surgery, which was mostly the effect of 
internal mechanisms of the body and not primarily due to weight loss (Guidone, 
et al., 2006). Taken from their research, Table 4 shows the levels of various 
measurements before BPD, 1 week after, and 4 weeks following BPD.  
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Table 4. Results Showing Levels Before, 1 Week after, and 4 Weeks After 
Biliopancreatic Diversion Surgery. Table X Data are means +/- SE. Significant 
differences were observed only between pre- and postoperation groups. *P < 
0.0001; †P < 0.001; ‡P < .05; §P < 0.01 (Guidone, et al., 2006). 
 
 Before BPD 1 Week After 
BPD 
4 Weeks After 
BPD 
 10 10 10 
Fasting glucose 
(mmol/l) 
7.79 +/- 0.10 5.92 +/- 0.42* 4.78 +/- 0.12* 
Fasting insulin 
(pmol/l) 
135.72 +/- 18.23 107.8 +/- 15.99 69.04 +/- 4.31† 
Fasting C-peptide 
(nmol/l) 
1.40 +/- 0.13 1.05 +/- 0.10 1.00 +/- 0.08‡ 
Fasting leptin 
(ng/ml) 
51.59 +/- 6.38 38.56 +/- 7.49* 31.03 +/- 3.73 
Fasting 
adiponectin 
(µg/ml) 
7.67 +/- 0.82 8.49 +/- 0.82 6.71 +/- 0.36 
Fasting GIP 
(pmol/l) 
13.40 +/- 1.99 6.58 +/- 1.72§ 5.83 +/- 0.80§ 
Fasting GLIP-1 
(pmol/l) 
1.75 +/- 0.16 3.42 +/- 0.41§ 3.62 +/- 0.21§ 
Glucose AUC 
(mmol/l) 
1, 704.52 +/- 
91.36 
1, 146.47 +/- 
88.52* 
1,079.02 +/- 
47.13* 
Insulin AUC 
(pmol/l) 
96,390.90 +/- 
12,681.51 
53,414.30 +/- 
8,617.14§ 
24,776.00 +/- 2, 
249.24 
C-peptide AUC 
(nmol/l) 
589.89 +/- 50.72 337.77 +/- 
52.38† 
289.36 +/- 24.87 
GIP AUC (pmol/l) 3,297.00 +/- 
440.60 
1,775.70 +/- 
189.76§ 
1,874.00 +/- 
169.60§ 
GLP-1 AUC 
(pmol/l) 
388.04 +/- 23.40 700.14 +/- 
84.71† 
721.46 +/- 
26.70* 
 
After BPD, subjects experienced a full reversal of diabetes supported by a 
normal range of fasting plasma glucose and glycemia 1 and 4 weeks after the 
operation. Shown under the column for 1 week after BPD are the levels of fasting 
plasma glucose, leptin, and GIP significantly decreased while fasting GLP-1 
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significantly increased, with no significant change in adiponectin. Four weeks 
following BPD, the levels of fasting plasma glucose was reduced further, while 
fasting plasma insulin and C-peptide significantly dropped. The levels of GIP and 
GLP-1 did not change significantly therefore perhaps the immediate changing 
levels following surgery are significant. 
Furthermore, Figure 14 shows the results of the levels of plasma glucose, 
insulin, GIP and GLP-1 before and after the surgery. There is a significant 
increase of GLP-1 following the surgery, and a decrease in GIP following 
surgery. Plasma glucose and insulin levels both drop 1 and 4 weeks after BPD. 
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Figure 14. Diabetes Reversal Following BPD: Levels of Glucose, Insulin, GIP, 
and GLP-1 (Guidone, et al., 2006).  
 
 
________________________________________________________________ 
Specifically looking at levels of AMPK as an option for the reversal of 
diabetes following bariatric surgery may be helpful. The study done by Gauthier, 
et al showed promising results. After putting together values for the 3 abdominal 
areas, they found that the activity of AMPK in visceral fat is lower than in 
subcutaneous fat, which is closely associated with increased inflammation and 
infiltration of immune cells (Gauthier, et al, 2011). Furthermore, they looked at 
the relationship between insulin resistance and AMPK activity (Gauthier, et al, 
2011). Here they found that there was a lower AMPK activity in all three depots 
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of obese insulin-resistant individuals versus those who had similarly matched 
BMI’s but were insulin-sensitive (Gauthier, et al, 2011). 
Regarding the role genetics plays in the disposition of NIDDM, the study 
by Walston, et al (2014) offered insight into a possible role of a mutation in the 
β3-adrenergic receptor gene.  
They initially looked at 10 obese Pima Indians who had NIDDM and 
screened them for any variations in the gene. After careful analysis, they found a 
silent replacement of cytosine by thymidine at nucleotide position 381 (Walston, 
et al, 1995). Furthermore, a second variation was found where there was a 
replacement of thymidine by cytosine at nucleotide position 190 (Walston, et al, 
1995). Because of these variations, a prediction was made about the 
replacement of tryptophan by arginine at position 64 (Trp64Arg) which is 
significant because that is an amino acid in the first of the three intracellular loops 
of the receptor for the gene (Walston, et al, 1995). From this discovery, the 642 
study subjects were genotyped for this Trp64Arg missense mutation in the β3-
adrengergic receptor gene where 9% were homozygous for the mutation, 45% 
were heterozygous, and 46% lacked the mutation (Walston, et al, 1995). While 
the findings from their research did not support that diabetes was significantly 
associated with the mutation, it did reveal that a higher number of those who 
were under the age of 25 and had been diagnosed with NIDDM were in the 
category of Trp64Arg homozygotes (Walston, et al, 1995). 
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CONCLUSION 
In conclusion, rather than the abnormality in the gene being a causative 
factor for NIDDM, they found that it accelerated the course of the disease and 
thus an earlier onset (Walston, et al, 1995). Therefore, having this mutation and 
thus an earlier onset of disease led to an increased mortality and possibly earlier 
death for those with the mutation and who developed NIDDM. 
Pooling together the various studies, overall, bariatric surgery does not 
only promote weight loss, but also may be used to treat obesity-related diseases 
including type 2 diabetes. Controlled weight loss via bariatric surgery does 
reduce mortality in morbidly obese patients along with decreasing co-morbidities. 
Furthermore, it seems that a decrease in caloric intake is not the sole explanation 
for the rapid reversal of diabetes, but rather other mechanisms may play a role in 
this. The two incretin hormones, GIP and GLP-1, secreted following a meal and 
are glucose-dependent insulin activators, play many roles in biological processes 
of the body. Furthermore, GIP has been shown to play a role relating 
overnutrition to obesity (Seino, Fukushimo, and Yabe, 2010). Due to their nature 
of rapid degradation, agonists for the GLP-1 receptor and inhibitors for dipeptidyl 
peptidase-4 have been used in the treatment for type 2 diabetes (Drucker, 2007). 
It is not without mentioning that genetics also plays a role in the 
predisposition to diabetes. Mutations in the β3-adrenergic receptor gene may 
accelerate the onset of disease and contribute to increase mortality. Therefore, in 
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addition to looking at levels of various biologic mechanisms of the body in 
patients who are both obese and normal weight, genetics should also be studied. 
Perhaps further studies may be done pooling together all of these findings. 
Further research should be done to see if bariatric surgery reverses diabetes in 
patients who are of normal weight but have NIDDM. Their levels of AMPK, 
SIRT1, and the incretin hormones GLP-1 and GIP should be closely monitored 
before and after the procedure. A control group could be used where they are 
patients who also have NIDDM but are of normal weight, but follow the 
conventional treatment of diet and exercise to see how they compare with those 
undergoing bariatric surgery. Additionally, family history and certain genes and 
any associated mutations should be accounted for. 
While diabetes has a high prevalence in the United States, there is hope 
that one day we will better understand its underlying mechanisms and the role 
bariatric surgery plays in its reversal. Perhaps because all of the varying causes, 
such as genetic, environment, lifestyle, and biological mechanisms of the body, it 
does add complexity for better understanding the disease. Nevertheless, many 
advancements have been made to overcome these obstacles and perhaps one 
day diabetes will be easily controlled and have less of a presence. 
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APPENDIX 
The following is from “The BMI Formula:” 
BMI Calculation 
Metric Formula: BMI = (weight in kilograms)/ (height in meters2) 
Imperial Formula: BMI = (weight in pounds*703)/ (height in inches2) 
Classifications 
Underweight = BMI < 18.5 
Normal Weight = BMI 18.5-24.9 
Overweight = BMI 25.0-29.9 
Obese = BMI 30.0+ 
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